Alpha-1 Antitrypsin Deficiency and Lung Cancer Risk: A Case–Control Study in Never-Smokers

Background: Never-smokers comprise up to 25% of all lung cancer cases. They could have different molecular pathways for lung cancer induction compared with smokers. Alpha-1 antitrypsin (AAT) deficiency is a hereditary trait whose main characteristic is early onset of lung emphysema. Our aim is to know if AAT-deficient carriers have a higher risk of lung cancer in a study performed exclusively in never-smokers. Methods: We designed a multicentre hospital-based case–control study, which included incident never-smoking lung cancer cases. Controls were never-smokers attending nonmajor surgery at the participating hospitals. Controls were frequency matched on age and gender with cases. We determined AAT variants (alleles S and Z) through polymerase chain reaction. Results: Two hundred and twelve cases and 318 controls were included. PiSS individuals showed a lung cancer risk of 4.64 (95% confidence interval: 1.08–19.92) compared with those with normal genotype (PiMM). When the analysis was restricted to women, the risk for PiSS increased to 7.58 (95% confidence interval: 1.40–40.87). This risk for homozygous SS was even higher for individuals exposed to environmental tobacco smoke (greater than 20 years). The presence of other alleles did not show any effect on lung cancer risk. Conclusions: Never smoking SS homozygous individuals pose an increased risk of lung cancer. The risk is higher for individuals exposed to environmental tobacco smoke.

[1]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2017, with focus on lung cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Fernández-Villar,et al.  Lung cancer in never-smokers: a case–control study in a radon-prone area (Galicia, Spain) , 2014, European Respiratory Journal.

[3]  A. Fernández-Villar,et al.  Residential radon and lung cancer in never smokers. A systematic review. , 2014, Cancer letters.

[4]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  F. D. de Serres,et al.  Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema , 2011, Orphanet journal of rare diseases.

[6]  D. Radojkovic,et al.  Alpha-1-antitrypsin Phenotypes and Neutrophil Elastase Gene Promoter Polymorphisms in Lung Cancer , 2011, Pathology & Oncology Research.

[7]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[8]  William Pao,et al.  Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications , 2009, Clinical Cancer Research.

[9]  E. Chan,et al.  α‐1‐Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood , 2009, Journal of leukocyte biology.

[10]  F. D. de Serres,et al.  Long-term augmentation therapy with alpha-1 antitrypsin in an MZ-AAT severe persistent asthma. , 2008, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[11]  W. Bamlet,et al.  Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. , 2008, Archives of internal medicine.

[12]  I. G. Clausen,et al.  TNF-alpha-induced self expression in human lung endothelial cells is inhibited by native and oxidized alpha1-antitrypsin. , 2008, The international journal of biochemistry & cell biology.

[13]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[14]  D. DeMeo,et al.  Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency , 2007, Thorax.

[15]  S. Vedal,et al.  Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency , 2006, International journal of chronic obstructive pulmonary disease.

[16]  Z. Jelić-Ivanović,et al.  Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population. , 2006, Archives of medical research.

[17]  M. Nusier,et al.  Relationship between alpha-1 antitrypsin deficient genotypes S and Z and lung cancer in Jordanian lung cancer patients. , 2006, Saudi medical journal.

[18]  L. Melton,et al.  α1-Antitrypsin and Neutrophil Elastase Imbalance and Lung Cancer Risk , 2005 .

[19]  L. Melton,et al.  Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. , 2005, Chest.

[20]  F. D. de Serres,et al.  alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. , 2005, Medical hypotheses.

[21]  I. Blanco,et al.  Déficit de alfa-1-antitripsina en España (variantes deficientes PI*S y PI*Z): prevalencia estimada y número de sujetos calculados para cada fenotipo , 2004 .

[22]  D. Lomas,et al.  α1-Antitrypsin deficiency • 4: Molecular pathophysiology , 2004, Thorax.

[23]  Zhifu Sun,et al.  Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. , 2004, The Lancet. Oncology.

[24]  D. Lomas,et al.  Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. , 2004, Thorax.

[25]  F. D. de Serres,et al.  [PI*S and PI*Z alpha 1-antitrypsin deficiency: estimated prevalence and number of deficient subjects in Spain]. , 2004, Medicina clinica.

[26]  S. Marcus,et al.  Activation of progelatinase A (MMP‐2) by neutrophil elastase, cathepsin G, and proteinase‐3: A role for inflammatory cells in tumor invasion and angiogenesis , 2001, Journal of cellular physiology.

[27]  I. Blanco,et al.  Alpha1-antitrypsin Pi phenotypes S and Z in Spain: an analysis of the published surveys. , 2001, Respiratory medicine.

[28]  R. Strausberg,et al.  High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  I. Blanco,et al.  [Allelic frequency of the gene of alpha-1-antitrypsin in the general population in a county in Asturias]. , 1999, Medicina clinica.

[30]  T. Lesnick,et al.  Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  D. Hutchison.  Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. , 1998, Respiratory medicine.

[32]  D. Lomas,et al.  Alpha 1-antitrypsin deficiency. A conformational disease. , 1996, Chest.

[33]  M. Miravitlles,et al.  [Study of the frequency of different phenotypes of alpha-1-antitrypsin in a population of Barcelona]. , 1996, Medicina clinica.

[34]  André Mj,et al.  [Evaluation of alpha 1-antitrypsin phenotypes in Castilla-León: study of a population of newborn infants]. , 1989 .

[35]  M. L. Arranz Peña,et al.  [Evaluation of alpha 1-antitrypsin phenotypes in Castilla-León: study of a population of newborn infants]. , 1989, Revista clinica espanola.

[36]  M. Fagerhol,et al.  Serum Pi types in some European, American, Asian and African populations. , 2009, Acta pathologica et microbiologica Scandinavica.

[37]  C. Laurell,et al.  The Electrophoretic α;1-Globulin Pattern of Serum in α;1-Antitrypsin Deficiency , 1963 .